PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention: Another Step Forward

Mark J. Alberts, Paul D. Thompson

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)1361-1362
Number of pages2
JournalStroke
DOIs
StatePublished - May 1 2020

Keywords

  • Editorials
  • atrial fibrillation
  • cardiovascular disease
  • evolocumab
  • sample size
  • secondary prevention
  • stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this